Through enzyme-linked immunosorbent assay (ELISA), we found Rplp0 knockdown and immunotherapy combination remarkably augmented the IFN-γ and TNF-α levels in serum (Figures 7I, J), which implies combinational treatment potentiated the anti-tumor immunity in mice. The gene discussed is TNF; the disease is neoplasm.